Evidence map›Paper›PMID 41938147›Full record

ArticleEndoscopic ultrasound

Prospective evaluation study of EUS-guided hepaticogastrostomy without tract dilation: Comparison to with tract dilation.

Mitsuki Tomita, Takeshi Ogura, Akitoshi Hakoda, Saori Ueno, Atsushi Okuda, Nobu Nishioka, Jun Matsuno, Nobuhiro Hattori, Junichi Nakamura, Takafumi Kanadani and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endoscopic ultrasound. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mitsuki Tomita2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Takeshi Ogura2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Akitoshi Hakoda2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Saori Ueno2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Atsushi Okuda2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Nobu Nishioka2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Jun Matsuno2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Nobuhiro Hattori2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Junichi Nakamura2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Takafumi Kanadani2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Kimi Bessho2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Hiroki Nishikawa2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: During EUS-guided hepaticogastrostomy (EUS-HGS), bile leak usually occurs in the interval between tract dilation and stent deployment. Recently, a novel partially covered self-expandable metal stent (PCSEMS) with fine gauge stent delivery system (5.9Fr) has become available. Therefore, the aim of this prospective study was to evaluate the technical feasibility of EUS-HGS using this novel stent without tract dilation and compare it with EUS-HGS with tract dilation. Method: Patients with biliary disease who required EUS-BD were eligible for enrollment in this study. The primary outcome was the technical success rate of stent deployment without tract dilation. Results: The technical success rate of the one-step technique was 92.0% (23/25). Mean procedure time was 10.1 min, and the clinical success rate was 96% (24/25). As adverse events, bile peritonitis and stent migration were observed in one patient each. As historical controls, 75 patients who underwent EUS-HGS were enrolled in this study. As adverse events, bile peritonitis was observed in eight patients and cholangitis in three patients. After propensity score matching analysis, procedure time was significantly shorter in the one-step group compared with the two-step group (9.84 Conclusions: In conclusion, EUS-HGS using this novel PCSEMS might be feasible and safe, and performance of tract dilation might influence the occurrence of bile peritonitis.

Indexed as

ERCPEUSEUS-HGSMalignant biliary obstructionTract dilation

Identifiers

PMID41938147
PMCPMC13048639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.